Response to "analysis of the Association Between Prospectively Collected Immune-Related Adverse Events and Survival in Patients with Solid Tumor Treated with Immune-Checkpoint Blockers, Taking into Account Immortal-Time Bias".

The search of predictive biomarkers for immune checkpoint inhibitor (ICIs) therapy remains a topic of major interest in oncology research. Previous studies have suggested that the development of immune-related adverse events (irAEs) can be associated with efficacy of ICIs in different cancer types [1-3]. However, statistical caveats such as the immortal-time bias or the publication bias may have overestimated this association [4]. Recently, Kfoury et alhave analysed 577 patients treated with anti-PD-(L)1 antibodies at Gustave Roussy Institute to evaluate the association of irAEs and efficacy outcomes after correctly accounting for immortal-time bias [5].